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Abstract
Background: This study aims to estimate the prostate-specific antigen density (PSAD) cutoff level for detecting
prostate cancer (CAP) in Nigerian men with “grey zone PSA” (4–10 ng/ml) and normal digital rectal examination
findings. We addressed this research question: Is the international PSAD cutoff of 0.15 ideal for detecting CAP in our
symptomatic patients with “grey zone PSA?”
Methods: Aim: To estimate the prostate-specific antigen density (PSAD) cutoff level for detecting CAP in Nigerian
men with “grey zone PSA” (4–10 ng/ml) and normal digital rectal examination findings.
Design: Prospective.
Setting: A tertiary medical center in Enugu, Nigeria.
Participants: Two hundred and fifty-four men with either benign prostatic hyperplasia (BPH) or CAP were recruited.
Intervention: Patients with PSA above 4 ng/ml or abnormal digital rectal examination or hypoechoic lesion in the
prostate were biopsied.
Outcome measures: PSAD and histology report of BPH or CAP.
Results: Ninety-seven patients had CAP while 157 had benign prostatic hyperplasia (BPH). Seventy-two patients
had their serum PSA value within the range of 4.0 and 10 ng/ml. PSAD cutoff level to detect CAP was 0.04
(sensitivity 95.88 %; specificity 28.7 %).
Conclusions: The PSAD cutoff level generated for Nigerian men in this study is 0.04 which is relatively different
from international consensus. This PSAD cutoff level has a positive correlation with histology and could detect
patients with CAP who have “grey zone PSA.”
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Background
There is significant morbidity and mortality associated
with prostate cancer (CAP), and recent studies have
shown that about 64 % of patients diagnosed with CAP
die within 2 years in Nigeria [1]. Unfortunately, there ap-
pears to be an increase in the incidence of CAP [2, 3].
There are concerted efforts to improve the screening
capability of serum total prostate-specific antigen (PSA)
necessitating the various modifications in PSA. Prostate-
specific antigen density (PSAD) is one of these
modifications.
PSAD estimates the PSA secreted per unit volume of
prostatic tissue. This is expected to be higher in malig-
nancy. Also, there has been documented variation in
PSA secreted per gram of tissue among different races
[4]. Asians for instance secrete more PSA per unit gram
of tissue compared to Caucasians [4], while blacks se-
crete even higher PSA per gram tissue than other races
when controlled for age, clinical stage, and Gleason
grade [5].
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Furthermore, the PSAD cutoff level of 0.15 for de-
tecting CAP developed from a study on Caucasians
and African Americans [6] has generated a lot of con-
troversies in recent times [7]. Some authorities believe
that when applied to other races or environments, it
is not very sensitive and as such could miss out ma-
lignant prostates if relied upon solely [7].
Unfortunately, in our environment, most patients
present to the clinicians only when they are symptom-
atic. This underscores the need to appraise the role of
PSAD cutoff level of 0.15 in the Nigerian setting.
This study undertakes to determine the difference
in prostate-specific antigen density values among our
patients with symptomatic benign prostatic hyperpla-
sia on one hand and symptomatic carcinoma of the
prostate on the other hand and then to estimate the
possible PSAD cutoff level with acceptable sensitivity
and specificity for detecting CAP among patients with
serum total PSA values in the “grey zone PSA” range




This study took place at the urology clinic of Enugu
State University Teaching Hospital Park Lane, Enugu,
Nigeria. Enugu is the major commercial city of Enugu
state, southeast Nigeria, with a population of 722,664.
This was a hospital-based prospective study consisting
of patients with symptomatic prostatic disease.
Study population
This was a hospital-based study and the subjects con-
sisted of patients with BPH and CAP diagnosed for the
first time.
Inclusion and exclusion criterion
The inclusion criteria consisted of all consented patients
who had symptomatic prostatic diseases and presented
for the first time to the clinic between November 2009
and December 2012 and were subsequently diagnosed to
have either benign prostatic hyperplasia (BPH) or CAP.
Excluded from the study were patients who have had
any form of treatment for BPH or CAP previously. Pre-
vious treatments such as 5 alpha reductase inhibitors,
gonadotropin-releasing hormone agonist, or orchiec-
tomy do affect PSA levels and prostate volume [8, 9],
both of which are used in determining PSAD. Also, ex-
cluded were those with coexisting urethral stricture and
diabetes mellitus as these could alter bladder dynamics.
In addition, those with other causes of lower urinary
tract symptoms were excluded.
Study method
Ethical clearance for the study was obtained from ESUT
Teaching Hospital Park Lane Ethical committee.
The sample size was calculated using the statistical
formula shown below:
N ¼ Z2PQ DEFFð Þ=δ2
[10]
where N =minimum sample size for a cross sectional
prospective study design;
Z = the standard normal deviation corresponding to
95 % level of significance. The value obtained from the
normal distribution table is 1.96. DEFF = estimated de-
sign effect = 1;
and P = prevalence rate; for BPH, prevalence rate is
21 % = 0.21 [11]; for CAP, prevalence rate is 13.3 % =
0.133 [3].
Q ¼ 1−Pð Þ
δ = absolute precision, i.e., the value required (in per-
centage points) which in actual term describes the max-
imum difference between the population rate and the
sample rate that can be tolerated; taken for this study to
be 10 % (0.01).
N ¼ 1:96
2  0:21 0:79
0:12
¼ 64 BPHð Þ;
N ¼ 1:96
2  0:13 0:867
0:12
¼ 44 for CAPð Þ:
Since two groups (BPH and CAP patients) were be-
ing compared in generating the PSAD cutoff level,
the minimum sample size for this study is 64 for each
group.
A total of 254 patients who met the inclusion criteria
were recruited for the study while 80 patients were ex-
cluded. All patients who met the inclusion criteria that
presented during the study period were recruited in the
study. Diagnosis of prostatic disease in this study was
both clinical and pathological. All subjects were evalu-
ated using international prostate symptom score and
digital rectal examination. They were screened by serum
prostate-specific antigen (ELISA method using-DS-EIA
PSA ELISA ITALY via xx Settembre).








BPH 157 64.04 ± 14.47 13.71 ± 17.46 93.06 ± 80.72
CAP 97 69.96 ± 11.67 49.86 ± 41.49 94.43 ± 52.11
T test P = 0.0021* P = 0.00* P = 0.88
*Significant p value
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The patients subsequently had abdominopelvic ultra-
sound. Those with serum PSA above 4 ng/ml or abnormal
digital rectal examination (DRE) findings or hypoechoic le-
sion on ultrasound had transrectal prostate biopsy. Ten bi-
opsies were taken using a disposable semi-automatic size
18GTrucut® biopsy needle, five from each prostate side.
The specimen of the biopsy were put in a bottle and fixed
in 10 % formalin and submitted to pathological department
for hematoxylin-eosin staining. The findings were classified
as adenocarcinoma or nodular hyperplasia. Histopatho-
logical studies were performed by the same pathologist.
The prostate volume was estimated by abdominopelvic
ultrasound (a GE logic S expert 052128 model ultrasound)
using a 3.5-MHz curvilinear scanner by a consultant radi-
ologist. The PSAD were calculated for all patients by div-
iding the serum PSA by the prostate volume [12].
Justification for the use of ultrasound in determination
of prostate volume was based on findings that have
proven that there was no statistical difference in prostate
volume measured by transrectal ultrasound compared to
abdominopelvic ultrasound [13–16].
Based primarily on the histology results (except for ten
subjects with clinical diagnosis of BPH), the subjects
were placed into two groups; those with CAP and those
with BPH.
The PSAD of the two groups were analysed to generate
a PSAD cutoff level for Nigerian men. The PSAD cutoff
level was applied to the patients with “grey zone PSA.”
These subset of patients had PSA between 4 and 10 ng/ml
and also had normal DRE and ultrasound findings. Subse-
quently, the specificity and sensitivity of the newly gener-
ated PSAD was compared with the universally accepted
PSAD cutoff level of 0.15 in this “grey zone PSA” group.
Statistical methods
For statistical analysis, STATA 13 (StataCorp LP, TX,
USA) was used to determine correlation and mean of vari-
ables. The correlation among variables was determined by
Pearson’s correlation coefficient; while linear regression
was used to determine relationship between variables. The
statistical program GraphPad Prism 5 software (GraphPad
Software Inc., CA, USA) was used to demonstrate the best
cutoff point for PSAD as well as to calculate its respective
sensitivities and specificities to predict CAP. The receiver
operating characteristics (ROC) curve was employed to
graphically demonstrate the sensitivities and specificities
of the PSAD. P < 0.05 statistically significant and with a
95 % confidence interval (CI).
Results
This study took place between November 2009 and
December 2012.
A summary of patient characteristics is presented in
Table 1. Two hundred and fifty-four patients completed
the study. Of the 254 patients, 157 patients had BPH,
while 97 had CAP.
Table 2 shows the characteristics of 72 patients with
“grey zone PSA” with normal DRE. There was no statis-
tical difference between the mean prostate volume of pa-
tients with CAP and patients with BPH. The mean PSA
values between the two groups differ significantly as
reflected by the P value (0.002).
The ages of patients ranged between 40 and 99 years.
Forty-six percent of patients were in the age range of
60–69 years (as shown in Fig. 1). Most of the patients
Table 2 Clinical characteristic of 72 patients with “grey zone









57 66.25 ± 9.96 5.41 ± 1.77 102.93 ± 87.75
CAP patients with
intermediate PSA
15 65.57 ± 20.55 7.06 ± 1.95 96.12 ± 52.42
T test P = 0.86 P = 0.002* P = 0.78
*P < 0.05 statistically significant
Fig. 1 Age distribution of patients in the study
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with BPH were in the age range of 60–69 years, while
for CAP, a greater percentage of patients were in the age
range of 70–79 years.
Figure 2 shows the variation in PSAD. The BPH pa-
tients whose PSAD values were less than 0.08 outnum-
bered the patients with CAP. However, beyond PSAD
value of 0.2 the reverse was the case.
Table 3 shows the mean PSAD value for BPH and
CAP which were 0.196 ± 0.325 and 0.77 ± 0.98, respect-
ively. There was statistical difference between mean
PSAD values of CAP and BPH.
Table 4 shows no statistical difference between mean
PSAD values of BPH and CAP in the “grey zone PSA.”
The discriminating power to detect CAP as esti-
mated by the ROC curve was 0.8177 for PSAD (area
under the curve 0.8188; SD 0.02664; 95 % CI 0.7666–
0.8710; P = 0.0001).
Estimates for sensitivity and specificity for different
PSAD cutoff points are shown in Fig. 3. The operation
characteristics of PSAD at maximum discrimination cut-
offs were computed. This was 0.04 for PSAD; the sensi-
tivity was 95.88 % and specificity was 27.8 %.
In establishing the relationship of PSAD cutoff level
with histology of patients using Pearson’s correlation co-
efficient, the correlation coefficient value was 0.31 with a
P value of 0.00 as shown in Table 5.
Table 6 shows the performances of the two different
PSAD cutoff levels in detecting CAP in patients with
“grey zone PSA.” The sensitivity of the new PSAD cutoff
level (0.04) in detecting CAP in the “grey zone PSA” is
86.7 % compared to 33.3 % for the conventional PSAD
cutoff level (0.15).
Discussion
A total of two hundred and fifty-four (254) patients were
recruited within the study period. They were all Niger-
ians from 45 to 99 years of age with mean PSA of 13.71
± 17.46 and 49.86 ± 41.49 ng/ml for BPH and CAP pa-
tients, respectively. Although there was statistical differ-
ence in PSA between CAP and BPH, the mean prostate
volume was not statistically different between the two
groups. This implies that the difference in PSA would
not be explained by the volume of the prostate; rather,
the distortion in the basement membrane could be the
likely explanation. Additionally, the mean prostate vol-
ume in our study comparatively was larger than the
mean prostate volume recorded in similar studies among
Caucasians [17]. However, it did not differ from the find-
ings in a local study carried out by Ugwumba et al. [18]
which showed a mean prostate volume of 100.7 mls.
Similarly, a study of ultrasonic determination of prostate
volume in Nigerian men with symptomatic BPH done by
Badmus et al. [19] had revealed a mean prostate volume
of 83.79 mls. Likewise, another study on peri-operative
blood transfusion in open suprapubic transvesical pros-
tatectomy: relationship with prostate volume and serum
total prostate-specific antigen revealed a mean
Fig. 2 Variations in PSAD between patients with BPH and patients with CAP
Table 3 Multi-variate analysis for all patients
Number Mean PSAD Median PSAD
BPH 157 0.196 ± 0.325 0.076
CAP 97 0.77 ± 0.98 0.42
T test P = 0.00*
*P < 0.05 statistically significant
Table 4 Multi-variate analysis for patients with “grey zone PSA”
Number Mean PSAD Median PSAD
BPH patients with
“grey zone PSA” range
57 0.081 ± 0.065 0.070
CAP patients with
“grey zone PSA” range
15 0.095 ± 0.053 00.071
T test P = 0.45
P < 0.05 statistically significant
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prostate volume of 90.4 cm3 for the Nigerian popula-
tion [20]. These findings may suggest that our study
population presented with significantly large prostatic
volumes.
For PSAD levels below 0.08, patients with BPH appear
to be more in number; beyond 0.2, those with CAP pre-
dominated. The operation characteristics of PSAD at
maximum discrimination cutoffs were computed as 0.04
with sensitivity of 95.88 % and specificity of 27.8 %. The
PSAD cutoff level of 0.04 was strongly positively corre-
lated to the histology of subjects. The new PSAD cutoff
level of 0.04 is more sensitive than the previously ac-
cepted PSAD cutoff level of 0.15 for detecting CAP
when applied to patients with “grey zone PSA” who are
symptomatic.
The observed variation in PSAD between BPH and
CAP noted in this study seems to agree with earlier
established facts that cancer of the prostate tend to pro-
duce more serum PSA than BPH. It is known that al-
though benign prostatic tissue secretes more PSA per
gram tissue, PSA is confined within the organ because of
intact blood basement membrane barrier [21]. Con-
versely, though carcinoma of the prostate secretes less
PSA per gram tissue compared to BPH, due to distorted
blood basement membrane barrier, a greater portion of
PSA is released in to the blood stream including the
complex forms [22].
The ideal cutoff level of PSAD for detecting CAP has
remained contentious in recent times. The previously
adopted cutoff level of 0.15 has come under vivacious
criticism from many scholars. Lujan et al. [7] in their
study, in which they dismissed the idea of using PSAD
cutoff level of 0.15 for detecting CAP, reported that
multivariate analysis failed to demonstrate any signifi-
cant association between PSAD (based on cutoff level of
0.15) and biopsy results. Moreover, if the recommended
cutoff of PSAD (>0.15) is used to prompt biopsy (instead
of performing biopsies based solely on serum PSA level
greater or equal to 4 ng/ml), as much as 30.6 % of the
cancers would remain undetected. They proposed that
PSAD cutoff level below 0.07 ng/ml/cc (100 % sensitive;
9 % specific) was most relevant in screening within the
“grey zone PSA” range. Although, Lujan et al. concluded
that PSAD was not relevant in screening patients in the
grey zone PSA if the cutoff level of 0.15 was applied.
They suggested that if 0.07 ng/ml/cc was applied, it
would be more relevant. This agrees with our findings
which suggested that a PSAD cutoff level 0.04 ng/ml/cc
would be more relevant in screening within the “grey
zone PSA” than the recommended cutoff level
(>0.15 ng/ml/cc).
Fig. 3 Receiver operating characteristics (ROC) curve depicting diagnostic accuracy of PSA density
Table 5 The relationship of PSAD cutoff level (0.04) with
histology of patients
Coefficient R value SD error P value
Pearson correlation coefficient 0.3097 – 0.00*
Linear regression 0.24 0.05 0.00*
*P < 0.05 statistically significant
Table 6 Performance of the PSAD cutoff levels in screening 72
patients with “grey zone PSA” (4–10 ng/ml)
PSAD cutoff levels 0.15 0.04
Sensitivity 33.3 %: 95 %
CI (20–41 %)
86.7 %: 95 %
CI (58–98 %)
Specificity 85.7 %: 95 %
CI (77–95 %)
20 %: 95 %
CI (10–33 %)
Positive predictive value 38.2 % 22.4 %
Negative predictive value 82.8 % 84.9 %
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This opinion was shared by Benson et al. [23] who in
their study conducted on 61 patients reported that only
two patients in the subset of CAP had a PSAD of less
than 0.05, and none of the patients with BPH had a
PSAD greater than 0.117. Based on this, they concluded
that a PSAD of greater than 0.15 was abnormal. These
studies affirmed that PSAD cutoff level of 0.15 ng/ml/cc
will not be relevant for screening. This explains why
PSAD was jettisoned as a tool for screening patients
with “the grey zone PSA.” However, adopting a PSAD
cutoff level of 0.04 ng/ml/cc generated a high sensitivity
of 95.88 % which made it more appropriate for screening.
Most studies in support of using PSAD to evaluate pa-
tients with “grey zone PSA” suggested a PSAD cutoff
level of 0.15 [24–26]. One of such recent studies was
done by Sfoungaristos et al. [27] in which they estimated
an optimal cutoff value of PSA density to be 0.15. This
was derived by ROC analysis (area under the curve
0.643, P = 0.001, 95 % CI 0.568–0.755). Comparing this
with our study, the area under the curve of the ROC
(area under the curve 0.8188; SD 0.02664; 95 % CI
0.7666–0.8710; P = 0.0001) in our study is different from
the generated value in their study, it appeared that selec-
tion of PSAD cutoff level in Sfoungaristos et al. [27]
study was based mainly on specificity without establish-
ing a convenient tradeoff between sensitivity and specifi-
city. Although, a high specificity will reduce false
positive results, thereby reducing unnecessary prostate
biopsy; a low sensitivity creates the problem of missing
out patients with cancer which is more harmful and
damaging to management protocol for CAP. Addition-
ally, it increases the cost of management of the disease
and the burden of missing out a patient with CAP far
outweighs the advantage of reducing unnecessary pros-
tate biopsy. As such, a balanced tradeoff between sensi-
tivity and specificity must be adopted in deriving a
cutoff level for PSAD in order to limit this flaw. In our
study, this was put into consideration in deriving the
PSAD cutoff level. The performance of the PSAD cutoff
level generated in our study, which showed a higher sen-
sitivity than the internationally accepted PSAD cutoff
level for patients with “grey zone PSA” (86.7 % and 20 %
respectively), attests to the advantage of attaching more
weight to sensitivity than specificity in generating PSAD
cutoff levels.
The new PSAD cutoff level of 0.04 generated in this
study is more appropriate for evaluating patients with
symptomatic prostatic enlargement. It may aid the urolo-
gist in making decisions for patients with “grey zone
PSA.” This may reduce unnecessary prostate biopsy.
These findings necessitate a more extensive multi-center
study with emphasis on a more balanced tradeoff between
sensitivity and specificity in deriving the most appropriate
PSAD cutoff level. Perhaps, PSAD may become more
relevant in the armamentarium of the urologist in
decision-making for cancer patients.
In summary, Nigerian men present with large prostatic
volumes compared to Caucasians. It is documented that
blacks secrete more PSA per unit tissue than Caucasians
[5], implying that large prostate volume may lead to
slightly elevated PSA. As such, PSAD estimation will be
relevant to our population. Depending on PSAD cutoff
level with high sensitivity appears to be relevant for
screening unlike PSAD cutoff level with specificity.
Strengths and limitations of this study
There is a possibility of missed cancers in the grey zone
PSA belt as a result of biopsy selection method.
The obvious trade-off of diagnostic testing of reduced
specificity as sensitivity is increased would increase the
number of patients subjected to unnecessary prostate
biopsy.
The sample population is heterogeneous.
Conclusions
In conclusion, the PSAD cutoff level generated for
Nigerian men in this study is 0.04 which is relatively
different from international consensus. This PSAD
cutoff level has a positive correlation with histology
and could detect patients with CAP who have “grey
zone PSA.”
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